| Similar Articles |
|---|
 |
The Motley Fool
December 22, 2010
Matt Koppenheffer |
Arena Pharmaceuticals Shares Plunged: What You Need to Know Shares of biopharma company Arena Pharmaceuticals dipped as much as 13% in intraday trading on massive volume.   |
The Motley Fool
December 3, 2010
Travis Hoium |
Orexigen Therapeutics Shares Plunged: What You Need to Know Shares of biopharmaceutical company Orexigen Therapeutics fell 10% today after a Food and Drug Administration announcement. |
The Motley Fool
June 3, 2011
Brian Orelli |
FDA Bullies Obesity Drugmakers It's been clear for some time that the Food and Drug Administration isn't particularly fond of obesity drugs. Now it's just being a bully. |
The Motley Fool
September 2, 2010
Luke Timmerman |
Orexigen Nabs $1B Deal With Takeda to Market Obesity Drug, Shares Climb San Diego-based Orexigen Therapeutics has found a partner to help it compete in the growing market for drugs to combat obesity, Japan-based Takeda Pharmaceutical. |
The Motley Fool
July 16, 2010
Luke Timmerman |
Vivus Obesity Drug Shot Down by FDA Panel Vivus suffered a setback today at an important meeting for the future of obesity drug development, with implications for Arena Pharmaceuticals and Orexigen Therapeutics. |
The Motley Fool
September 2, 2010
Brian Orelli |
Fatter Wallet. Up 22%. Still Risky. After VIVUS' Qnexa was shot down at its FDA advisory panel, it's clear that Arena and Orexigen have an uphill battle in front of them. |
The Motley Fool
July 13, 2010
Brian Orelli |
A Triple Delight: 3 Stocks All Up More Than 10% What's good for the obese goose is good for the gander when it comes to new drug treatments for losing weight. |
The Motley Fool
July 16, 2010
Jordan DiPietro |
Why Did These Stocks Plunge? A look at the prior day's biggest losers: Orexigen... Arena Pharmaceuticals... DragonWave... |
The Motley Fool
December 3, 2010
Brian Orelli |
Obesity Drug Companies Are (Still) Risky Orexigen heads before an FDA panel. |
The Motley Fool
October 11, 2010
Brian Orelli |
What Meridia's Demise Means for Arena, VIVUS, and Orexigen Safety first ... and second ... and third... |
The Motley Fool
June 3, 2011
Luke Timmerman |
Orexigen, Facing High Hurdle at FDA, Puts Obesity Drug Development on Hold The close attention paid to safety makes this drug difficult to get right. |
The Motley Fool
June 1, 2011
Brian Orelli |
Not All "Regulatory Updates" Are the Good Kind Orexigen gives an update; investors update their holdings. |
The Motley Fool
September 21, 2011
Brian Orelli |
Obesity-Drug Makers Stop Getting Bullied The drugs are still relative long shots being developed by companies that may have to raise more cash between now and an approval. |
The Motley Fool
February 1, 2011
Brian Orelli |
Orexigen Falls Short Its obesity drug fails in the final mile of the drug-development marathon. |
The Motley Fool
December 8, 2010
Brian Orelli |
Up 100% With Room to Fly Orexigen gets a positive FDA panel nod. |
The Motley Fool
September 9, 2009
Brian Orelli |
Weight Down. Stock Price Up. Really Up. Positive phase 3 trials will do that for VIVUS' anti-obesity drug, Qnexa |
The Motley Fool
September 21, 2011
Luke Timmerman |
Orexigen Revives Obesity Drug After One More Go-Round With FDA Orexigen has new life. |
The Motley Fool
June 25, 2010
Brian Orelli |
Mark Your Calendars: Obesity Drugs Take Center Stage Orexigen Therapeutics has been given an FDA advisory committee meeting date, completing the dates for the trio of obesity drugs up for review. |
The Motley Fool
May 27, 2011
Brian Orelli |
Don't Believe the Obesity Hype Meta-analysis data isn't going to help Arena Pharmaceuticals' obesity drug. |
The Motley Fool
November 23, 2009
Brian Orelli |
The Side Effect of Developing Obesity Drugs The FDA is fickle when it comes to weight-loss drugs. |
The Motley Fool
September 16, 2010
Brian Orelli |
Abbott's Product Line May Get Thinner Not that it needs the obesity drug. |
The Motley Fool
February 11, 2011
Brian Orelli |
Biotech Optimists Throw In the Towel As the chance of survival improves, the stock falls. Wait, what? |
The Motley Fool
March 18, 2008
Brian Orelli |
Lack of Side Effects Doesn't Fatten Arena Good safety data on its obesity drug fails to plump up Arena's stock price. Investors, take note. |
The Motley Fool
October 25, 2010
Brian Orelli |
Arena's Boring News The Food and Drug Administration turned down Arena Pharmaceuticals' obesity drug, lorcaserin. Tell us something we didn't know. |
The Motley Fool
September 18, 2009
Brian Orelli |
Up, Down, Up. Is This Stock a Home Run or Not? Shares of Arena Pharmaceuticals have been on a roller coaster after word that the company would release data for its obesity drug. |
The Motley Fool
October 19, 2010
Brian Orelli |
Why the FDA Won't Approve Lorcaserin and Qnexa (Yet) Obesity drugs get their day in front of the agency. |
The Motley Fool
September 14, 2010
Brian Orelli |
42% Drop? Really? Tell Us Something We Didn't Know. Arena Pharmaceuticals gets knocked down for no good reason. |
The Motley Fool
July 14, 2010
Luke Timmerman |
Vivus Faces Turning Point Tomorrow Thursday's the big day. All eyes will be on Vivus and the FDA's decision on their new obesity drug |
The Motley Fool
July 2, 2010
Brian Orelli |
Arena Got Taken A billion-dollar market and that's all the pharmaceuticals company could get? |
The Motley Fool
April 5, 2011
Brian Orelli |
Obese Expectations Trump Great Data Sorry VIVUS and Orexigen, you're still not going to get your drugs approved quickly. |
The Motley Fool
December 12, 2008
Brian Orelli |
The Skinny on the Latest Drug Trial VIVUS' obesity treatment data looks good, but will its drug be a marketing success? |
The Motley Fool
December 22, 2010
Brian Orelli |
Arena Charges On It seems Fool readers were a little more optimistic about the timing of Arena Pharmaceuticals' resubmission of its obesity drug to the Food and Drug Administration than the company is. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
The Motley Fool
September 21, 2010
Brian Orelli |
Double-Digit Weight Loss, Double-Digit Share Increase Vivus is down, but apparently not out. |
The Motley Fool
June 28, 2010
Luke Timmerman |
Orexigen Drug Shows Potential as "Two-Fer" Against Obesity and Diabetes Orexigen's latest drug aims at treating both diabetes and obesity. |
The Motley Fool
March 30, 2011
Brian Orelli |
This Share Count Might Need Some Obesity Meds Soon Arena gets some dilutive financing. |
The Motley Fool
January 4, 2012
Brian Orelli |
This Biotech's Obese To-Do List Is Done Arena resubmits lorcaserin for FDA approval. |
The Motley Fool
November 9, 2010
Brian Orelli |
Arena Pharmaceuticals Scores Some Points Overall, the recent Bloom-DM study leaves Arena in a slightly better position than it was in before the data was released, but this battle to get lorcaserin approved is far from over. |
The Motley Fool
January 28, 2011
Brian Orelli |
Arena's Obese To-Do List The Food and Drug Administration's laundry list for Arena Pharmaceuticals seems to be getting longer. |
The Motley Fool
March 17, 2011
Brian Orelli |
Taking a Bite Out of Amylin's Obesity Drug Potential Amylin Pharmaceuticals and Takeda announce they were putting a hold on the development of their obesity drug combination pramlintide/metreleptin due to safety issues. |
The Motley Fool
December 31, 2009
Brian Orelli |
2010 FDA Decisions to Watch It's a pivotal year for these drugmakers. |
The Motley Fool
January 9, 2012
Brian Orelli |
Don't Believe This Company's Warning VIVUS' news is great news. |
The Motley Fool
September 17, 2010
Brian Orelli |
Thanks for Nothing, Fen-Phen Arena gets knocked down despite a relatively clean side-effect profile. |
The Motley Fool
September 14, 2010
Luke Timmerman |
Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug. |
The Motley Fool
September 20, 2010
Jordan DiPietro |
Why Did These Stocks Plunge? Let's look at some stocks that plunged on Friday, and examine whether any logic justified their shift |
The Motley Fool
March 31, 2011
Brian Orelli |
Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good. |
The Motley Fool
July 16, 2010
Brian Orelli |
Why VIVUS Is 57% Thinner In a move that slashed the pharmaceutical's shares, Food and Drug Administration advisory committee recommended that the agency not approve their obesity drug Qnexa. |
The Motley Fool
February 26, 2011
Brian Orelli |
FDA Applications and a Look Ahead It isn't pretty. |
The Motley Fool
May 4, 2011
Brian Orelli |
VIVUS Unveils Its Obesity Plans Investors are getting fat on the news that VIVUS has a plan, and a backup plan, to get its obesity drug Qnexa on the market. |
The Motley Fool
March 2, 2011
Susmita Chatterjee |
How to Capitalize on the Obesity Epidemic Does broader use of Allergan's Lap-Band signify competition for others? |
